Evidence map›Paper›PMID 37519788›Full record

ArticleFrontiers in oncology2023

Long-term outcomes of symptomatic optic pathway glioma: 32-year experience at a single Western Australian tertiary pediatric oncology center.

Revathi Rajagopal, Mumtaz Khan, Robert Lethbridge, Gabriel Lee, Sharon Lee, Jason Dyke, Vicki Fabian, Alycea McGrath, Mandy Taylor, Peter Jacoby and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Revathi RajagopalDepartment of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, United States.
Mumtaz KhanDepartment of Anesthesia, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Robert LethbridgeSchool of Pediatrics and Child Health, University of Western Australia, Perth, WA, Australia.
Gabriel LeeDepartment of Neurosurgery, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Sharon LeeDepartment of Neurosurgery, Perth Children's Hospital, Perth, WA, Australia.
Jason DykeDepartment of Neuropathology, Royal Perth Hospital, Perth, WA, Australia.
Vicki FabianDepartment of Neuropathology, Royal Perth Hospital, Perth, WA, Australia.
Alycea McGrathDepartment of Radiation Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Mandy TaylorDepartment of Radiation Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Peter JacobyDepartment of Biostatistics, Telethon Kids Institute, The University of Western Australia, Perth, WA, Australia.
Raelene EndersbyBrain Tumor Research Program, Telethon Kids Institute, The University of Western Australia, Perth, WA, Australia.
Sumanth NagabushanKids Cancer Centre, Sydney Children's Hospital, Sydney, NSW, Australia.
Nicholas G GottardoBrain Tumor Research Program, Telethon Kids Institute, The University of Western Australia, Perth, WA, Australia.
Sir Charles Gairdner Hospital · AUUniversity of Western Australia · AURoyal Perth Hospital · AUPrincess Margaret Hospital for Children · AUSt. Jude Children's Research Hospital · USThe Kids Research Institute Australia · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Optic pathway gliomas (OPGs) are associated with significant risk of visual and endocrine morbidity, but data on long-term outcomes in symptomatic patients is sparse. This study reviews the clinical course, disease progression, survival outcomes and long-term sequelae in pediatric patients with symptomatic OPGs in our institution over three decades. Methods: Retrospective review of patients with symptomatic OPG treated in a single tertiary pediatric oncology center from 1984 to 2016. Results: A total of 37 patients were diagnosed with symptomatic OPG. Decreased visual acuity was the commonest presenting symptom (75.7%). Surgical intervention was performed in 62.2%; 56.5% underwent biopsy, 26.1% surgical debulking and 17.4% had orbital decompression with cystic fenestration and cosmetic optic nerve excision at different treatment intervals. CSF diversion was performed in 47.8% patients. Histopathologic examination confirmed 86% to be pilocytic astrocytoma and 1 ganglioglioma. 46% received chemotherapy and 48% had radiotherapy, at different intervals. Median follow-up was 13.74 years. In NF1 patients, overall survival (OS) was 100% at 5 years and 55.6 ± 24.8% at 25 years while progression-free-survival (PFS) was 50 ± 15.8% at 5 and 20 years. In non-NF1 patients, OS was 96.2 ± 3.8% at 5 years and 87.4 ± 9% at 25-years. 5-year PFS was 53.8 ± 9.8% and 25-year PFS was 49.0 ± 10%. Cumulative PFS was 53 ± 8.3% at 5 years and 49.7 ± 8.4% at 20 years while cumulative OS was 97.2 ± 2.7% at 5 years and 77.5 ± 10.8% at 25 years. 59.5% patients developed post-operative endocrinopathy. Long-term vision was normal in 8.1%, improved in 13.5%, stabilized in 40.5% but worsened in 37.8% patients. Three patients treated with radiotherapy developed second brain tumors. Conclusion: 25-year OS in this cohort was 77.5% but survivorship carried significant long-term morbidities including radiation-induced second malignant brain tumors.

Indexed as

endocrinelong-termoptic gliomaoutcomessecond malignanciessymptomaticvisual

Identifiers

PMID37519788
PMCPMC10379632
OpenAlexW4384406459

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.